Exclusive enteral nutrition continues to be first line therapy for pediatric Crohn's disease in the era of biologics
| Autor: | M.I. Vicioso Recio, M.J. Serrano Nieto, C. Sierra Salinas, S. Lacasa Maseri, Javier Blasco-Alonso, F. Girón Fernández-Crehuet, Víctor Manuel Navas-López |
|---|---|
| Jazyk: | Spanish; Castilian |
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
Crohn's disease business.industry Medical record Nutrición enteral exclusiva Disease medicine.disease Inflammatory bowel disease Gastroenterology Pediatrics RJ1-570 Therapeutic approach Parenteral nutrition Intestinal mucosa Enfermedad inflamatoria intestinal Management of Technology and Innovation Internal medicine Calprotectina medicine Calprotectin Enfermedad de Crohn business |
| Zdroj: | Anales de Pediatría (English Edition), Vol 83, Iss 1, Pp 47-54 (2015) |
| ISSN: | 2341-2879 |
| Popis: | Background: Exclusive enteral nutrition (EEN) has been shown to be more effective than corticosteroids in achieving mucosal healing without having their side effects. Objectives: To determine the efficacy of EEN in terms of inducing clinical remission in newly diagnosed CD children and to study the efficacy of this therapeutic approach in improving the degree of intestinal mucosa inflammation. Materials and methods: The medical records of patients with newly diagnosed Crohn's disease treated with EEN were reviewed retrospectively. The degree of mucosal inflammation was assessed by fecal calprotectin (FC). Remission was defined as a PCDAI |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|